A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Clinical trial NCT01880424 · COMPLETED

Trial details

NCT number: NCT01880424
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Irritable Bowel Syndrome With Constipation (IBS-C)

Start date: 2013-07-01
Primary completion: 2015-05-01
Enrollment: 1722

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.